Hervolution is pleased to announce a new, exciting collaboration with Dr. Martin Gleave who joins the company as a scientific advisor. Dr. Gleave is a urologic surgeon and Distinguished Professor and Chair of the Department of Urologic Sciences at University of British Columbia, Canada. He is also co-founder and Executive Director of the highly respected Vancouver Prostate Center (VPC).

With Dr. Gleave as a scientific advisor, Hervolution will be able to get valuable insights into the development in prostate cancer research in the years to come. Not least, Dr. Gleave will play a key role for Hervolution when it comes to positioning HERV-K immunotherapy in the prostate cancer space.

“We are very pleased with the contact with Dr. Gleave. He is a capacity within prostate cancer research and a coordinator of clinical research of impressive scope. Access to advice at this level will help us position our technology within prostate cancer treatments, which is highly complex and continuously evolving,” says Hervolution’s CEO, Peter J. Holst.

Dr. Gleave, who has published more than 560 papers and been appointed to the Order of Canada, is looking forward to working together with Hervolution and helping the company.

“Hervolution promotes a highly interesting technology ideally suited for a novel target in human cancers. I wished to collaborate with them and support their work towards developing novel therapies for advanced prostate cancer,” says Dr. Gleave.

Dr. Martin Gleave joins an international group of scientific advisors, all of whom are capacities within oncology or HERV research. Two of them are Dr. Jay Berzofsky, Chief of NCI Center for Cancer Research Vaccine Branch, who runs clinical trials on immunotherapy in breast aDr. Martin Gleave joins Hervolution as scientific advisor
nd prostate cancer, and Dr. Sharon Glynn, Senior Lecturer at the National University of Ireland, Galway, who studies the role of HERV-K in prostate cancer and breast cancer.